Wegovy and Constipation: What the Clinical Evidence Shows

Why Wegovy slows things down: the mechanism behind semaglutide constipation

Semaglutide activates GLP-1 receptors in the gut, which reduces the speed at which the stomach empties and slows transit through the bowel. That slowing is part of how the medicine works, it prolongs the sensation of fullness and blunts appetite. The downside is that slower transit gives the colon more time to draw water from stool, which is the classic route to constipation that people taking Wegovy commonly ask about. The NHS semaglutide medicines page lists constipation among the common side effects you might notice.

Food intake also tends to fall sharply in the first weeks of treatment. Less food means less bulk moving through the bowel, which compounds the problem. Some people also drink less without thinking about it, because their appetite suppression dulls the sensation of thirst alongside hunger. Reduced fibre and fluid together can turn mild sluggishness into something more uncomfortable.

Dose increases are a particular flashpoint. Each time the dose steps up, the gut-slowing effect reasserts itself before the body has a chance to adapt. Many people find constipation eases after a few weeks at a stable dose, only to return briefly at the next increase. That pattern is consistent with what was observed across the STEP programme and matches the experience our prescribers hear about regularly.

Practical steps that may help, and the limits of self-management

Hydration is the first practical measure worth addressing. Keeping water near wherever you take your morning tablet or inject each week (a glass left beside the kettle, say) makes it easier to build the habit. The NHS broadly advises around six to eight cups of fluid a day, though needs vary. Gentle increases in dietary fibre (vegetables, pulses, wholegrains) can help, introduced gradually to avoid bloating. Soluble fibre in particular absorbs water and softens stool.

Low-impact movement (walking, for example) supports bowel motility in a way that sitting for long stretches does not. Establishing a consistent toilet routine, going at the same time each day rather than waiting for urgency, also matters more than it sounds. For managing constipation on Wegovy beyond these basics, there is more detail on specific approaches that some people find useful.

Over-the-counter laxatives are available, but before reaching for them it is worth speaking to a pharmacist or your prescriber. Not all laxative types suit everyone on a GLP-1 medicine, and some interact with medicines that affect gut motility. Self-treating persistent constipation without guidance is not always the right call. If you want a structured view of what treatment options exist, it is worth reading through the evidence rather than trial and error.

When constipation on Wegovy needs medical attention

Most constipation on Wegovy is uncomfortable rather than dangerous. But there are situations where you should not wait it out. Severe or persistent stomach pain (especially pain that radiates through to the back) combined with vomiting is not a constipation symptom to manage at home. It may indicate pancreatitis, which the MHRA flagged in a Drug Safety Update for GLP-1 medicines in January 2026 as an infrequent but serious risk. Stop the medicine and seek urgent care if that pattern appears.

Other signs that warrant calling your GP or 111 rather than waiting: complete inability to pass stool or wind for several days, significant abdominal swelling or bloating, blood in stool, or constipation accompanied by signs of dehydration (dark urine, dizziness, rapid heartbeat). Prolonged severe constipation that does not respond to simple measures, or that begins suddenly without a clear relationship to a dose change, also deserves a clinical eye rather than self-management alone.

If something feels wrong but is not an emergency, our prescribers are available for aftercare seven days a week. And anyone who suspects Wegovy contributed to an unusual or severe symptom can report it directly via the Yellow Card scheme, both patients and healthcare professionals can submit reports there. It helps build the national picture of how these medicines perform in real-world use.

Constipation, context, and what this means for your treatment

Constipation is one of several gastrointestinal side effects discussed in our broader guide to Wegovy's side effects, and it sits alongside nausea and reflux as something that many people experience at some point during treatment. The frequency data from the STEP trials suggests it affects a significant minority, not everyone, but enough that it is worth knowing about before you start.

It is also worth remembering that semaglutide constipation is not unique to Wegovy. The underlying pharmacology of GLP-1 receptor agonists produces broadly similar gut effects across the class, which is why the same discussion comes up for people asking about whether Wegovy causes constipation specifically, and for those already in treatment wondering how to manage it. The question our clinical team fields most often is whether constipation means treatment should stop. Usually it does not, but that is a clinical judgement, not a blanket answer.

If constipation is a concern going into treatment, or has become a problem during it, speak to our prescribers as part of your consultation. Side effects, including this one, are part of what a proper clinical assessment is for.